Currently, very few therapeutic options are available for HCC but also other hepatic cancers (i.e., ICC, hepatoblastoma), and thus a better understanding of TIA1 but also of other AUBPs may provide new biomarkers and/or novel and efficient therapeutic options. This evidence concerns the gene TIA1 and hepatoblastoma.